Navi Nifty 500 Multicap 50:25:25 Index Fund
The scheme seeks to achieve return equivalent to Nifty 500 Multicap 50:25:25 Index by investing in stocks of companies comprising Nifty 500 Multicap 50:25:25 Index, subject to tracking error.
Growthvine rating: 1/5 — ranked #30 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹10.18 (as of 2026-11-13) |
|---|
| AUM | ₹28 Cr |
|---|
| Expense ratio | 0.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Rushabh Patel |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −20.02% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 95.3% of NIFTY500 Multicap 50:25:25's upside and 101.0% of its downside.
Market cap allocation
| Large cap | 52.1% |
|---|
| Mid cap | 24.1% |
|---|
| Small cap | 23.8% |
|---|
Concentration
| Top 5 holdings | 15.4% |
|---|
| Top 10 holdings | 22.3% |
|---|
| Total holdings | 498 |
|---|
| Index overlap | 99.7% |
|---|
| Active share | 0.3% |
|---|
Top holdings
- HDFC Bank Ltd. — 4.2%
- ICICI Bank Ltd. — 4.0%
- Reliance Industries Ltd — 3.1%
- Bharti Airtel Ltd. — 2.4%
- Larsen & Toubro Limited — 1.8%
- Infosys Ltd — 1.6%
- State Bank Of India — 1.6%
- AXIS Bank Ltd. — 1.4%
- Kotak Mahindra Bank Ltd. — 1.3%
- Bajaj Finance Limited — 1.0%
Top sectors
- Banking & Financial — 19.7%
- Automobile — 7.7%
- Pharma & Biotech — 6.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 1.1% | Q4 (Bottom) | #26 of 33 |
| 2025 | 4.0% | Q2 | #12 of 30 |